Carbon dioxide/perflubron

Drug Profile

Carbon dioxide/perflubron

Alternative Names: Carbon dioxide/perfluorooctyl bromide; Perflubron/carbon dioxide; S-1226

Latest Information Update: 27 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SolAeroMed
  • Class Antiasthmatics; Fluorocarbons; Inorganic carbon compounds; Oxides; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 13 May 2016 Safety data from a phase I trial in Asthma (In volunteers) presented at the Conference of the American Thoracic Society (ATS-2016)
  • 14 Jan 2015 Phase-II clinical trials in Asthma in Canada (Inhalation)
  • 13 Jan 2015 SolAeroMed plans a phase IIa trial for Asthma in Canada (NCT02334553)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top